The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Patient- vs physician-reported symptom burden in MPN: A GSG-MPN intraindividual analysis
|
MPN are associated with numerous symptoms that can severely impact patient QoL and ability to conduct activities of daily living.1 Whilst previous studies have demonstrated differences in patient- vs physician-reported MPN symptom burden, studies directly comparing perception of symptom burden between matched patient and physician responses are lacking.1 Manz et al.1 conducted a retrospective analysis of data from 3,979 patients with MPN (38% ET, 33% PV, 21% PMF, and 8% other/unclassified MPN) from the GSG-MPN Bioregistry to provide an intra-individual comparison of patient- and physician-reported symptom burden, with a focus on the impact of symptom burden on OS. Patient symptom ratings were assessed using a modified MPN-SAF-TSS assessment and matched with physician assessments conducted within 3 months. Findings were published in Leukemia.1
|
| Key learnings |
| 93% of patients reported the presence of ≥1 symptom at baseline, with severe disease burden reported by 38% of patients. Severe patient-reported symptoms were an independent risk factor for death. All symptoms were reported more frequently by patients than physicians. |
|
Fatigue was the most commonly reported symptom by both patients and physicians. However, reports of fatigue were significantly different between patients (82% to 85%) and physicians (26% to 36%) (p < 0.001). |
| Sleep hyperhidrosis, pain, and pruritus were the second most commonly reported symptoms, followed by weight loss and fever. Pruritus was reported most commonly in PV by both patients (60%) and physicians (27%) (p < 0.001). |
|
These findings suggest significant discrepancies in symptom recognition between patients and physicians (with physicians underestimating the presence of symptoms) and demonstrate the association of severe patient-reported outcomes with survival, highlighting the need for careful patient-reported symptom assessment using validated tools, both in routine clinical practice and clinical trials. |
Abbreviations: ET, essential thrombocytosis; GSG-MPN, German Study Group for Myeloproliferative Neoplasms; MPN, myeloproliferative neoplasms; MPN-SAF-TSS, Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score; OS, overall survival; PMF, primary myelofibrosis; PV, polycythemia vera.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
